XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor conferences:

  • 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 am ET. The live webcast of the fireside chat can be accessed .
  • 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 3:00 pm ET. The live webcast of the company presentation can be accessed .

Details on company presentations and the links to webcasts can be found on the “Investors” section of Xenon’s website at . When available, webcasts will be posted for replay following the event for 30 days. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email:



EN
08/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

 PRESS RELEASE

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Xenon Reports Second Quarter 2025 Financial Results & Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOB...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch